Introduction

Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2020.11439

OL-0-0-11439

Articles

Comprehensive gene and pathway analysis of cervical cancer progression

Yuexiong

* Fang

Yan

* Wu

Kejia

Liu

Yanyan

Zhang

Wei

Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, P.R. China

Correspondence to: Professor Wei Zhang, Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, Hubei 430071, P.R. China, E-mail: zw6676@163.com *

Contributed equally

04 2020

03 03 2020

19 4 3316 3332 24062019 15012020

2020

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cervical Cancer is one of the leading causes of cancer-associated mortality in women. The present study aimed to identify key genes and pathways involved in cervical cancer (CC) progression, via a comprehensive bioinformatics analysis. The GSE63514 dataset from the Gene Expression Omnibus database was analyzed for hub genes and cancer progression was divided into four phases (phases I–IV). Pathway enrichment, protein-protein interaction (PPI) and pathway crosstalk analyses were performed, to identify key genes and pathways using a criterion nodal degree ≥5. Gene pathway analysis was determined by mapping the key genes into the key pathways. Co-expression between key genes and their effect on overall survival (OS) time was assessed using The Cancer Genome Atlas database. A total of 3,446 differentially expressed genes with 107 hub genes were identified within the four phases. A total of 14 key genes with 11 key pathways were obtained, following extraction of ≥5 degree nodes from the PPI and pathway crosstalk networks. Gene pathway analysis revealed that CDK1 and CCNB1 regulated the cell cycle and were activated in phase I. Notably, the following terms, ‘pathways in cancer’, ‘focal adhesion’ and the ‘PI3K-Akt signaling pathway’ ranked the highest in phases II–IV. Furthermore, FN1, ITGB1 and MMP9 may be associated with metastasis of tumor cells. STAT1 was indicated to predominantly function at the phase IV via cancer-associated signaling pathways, including ‘pathways in cancer’ and ‘Toll-like receptor signaling pathway’. Survival analysis revealed that high ITGB1 and FN1 expression levels resulted in significantly worse OS. CDK1 and CCNB1 were revealed to regulate proliferation and differentiation through the cell cycle and viral tumorigenesis, while FN1 and ITGB1, which may be developed as novel prognostic factors, were co-expressed to induce metastasis via cancer-associated signaling pathways, including PI3K-Art signaling pathway, and focal adhesion in CC; however, the underlying molecular mechanisms require further research.

cervical cancer bioinformatics analysis diagnosis progression

Introduction

Cervical Cancer (CC) is a highly aggressive tumor and is one of the leading causes of cancer-associated mortality in women, with an estimated 570,000 new cases and 311,000 deaths in 2018 worldwide (1). Women with CC are considered to have a lower quality of life (2). The progression of CC, from normal cervical mucosal epithelium to cervical intraepithelial neoplasia (CIN) grade 1, 2, and 3, to CC (3) is associated with persistent high-risk human papillomavirus (HPV) infection (4). Furthermore, a number of risk factors, including early sexual activity (5), multiple sexual partners (6), long-term use of oral contraceptives (7), genetic factors [active oncogenes, including PIK3CA (8), ATAD2 (9) and CRNDE (10); tumor suppressor genes, including p53 (11), Ras association domain family 1 isoform A (12) and NOL7 (13)], tobacco use [current smoker, started smoking age ≤15 years, smoking duration ≥30 years, ≥20 cigarettes/day (14)] and other viral infections (such as HIV, herpes simplex virus (HSV) type II and bacterial infections caused by Chlamydia trachomatis) (15) have been associated with CC progression.

HPV infection plays a leading role in CC (16). The DNA of HPV integrates into the host cell genome [HPV16: q21-q31 of chromosome no. 13; HPV18: q24 of chromosome no. 8 (17)], disrupts the open reading frame and causes overexpression of E6 and E7 genes (18). It has been verified that E6 and E7 exert carcinogenic effects by binding to the cell cycle regulators, p53 and retinoblastoma (Rb) (19). While E6 and E7 proteins are upregulated, E6 can interact with its associated protein [E6-associated protein, E6AP (20)] to form a complex and bind to p53. This binding hydrolyzes p53 and results in the loss of p53-induced negative regulation of cell proliferation, thereby leading to unchecked cellular proliferation and malignant transformation (21). E7 has a high affinity for Rb, which controls the cell cycle. Binding of E7 to Rb can dissociate the Rb-E2F complex, thus releasing E2F to exert its role as a transcription factor, which leads to an uncontrolled cell cycle and cellular immortalization (22,23). Furthermore, centrosomes are central regulators of mitosis that are often increased in numbers in cancer cells (24). A previous study indicated that an abnormally increased number of centrosomes is associated with structural chromosomal abnormality in cervical lesions with high risk of HPV infection (25). Duensing and Münger (26) reported that abnormal number of centrosomes and associated spindle mitotic abnormality can be found in cells infected by the high-risk HPV16 E6 and E7 proteins, but not in cells infected by the low-risk HPV6. Although numerous experimental studies on genes [HPV16 L1 protein (27), sonic hedgehog (28) and FGFR4 (29)], and signaling pathways [Wnt/β-catenin signaling pathway (30), adenosinergic pathway (31) and ERK signal transduction (32)], as well as bioinformatics analyses have focused on microRNAs (33) and genes (34) associated with CC, and have provided an understanding of the pathophysiological mechanisms of the disease over the last decade, the underlying molecular mechanisms remain unclear.

The development of CC occurs over a number of years and its complexity presents clinical challenges in patients screening and treatment. Currently, The Bethesda System (35), which is a tool that is used to report Pap smear results for cervical cytologic diagnoses, provides useful data that allows research into the epidemiology, biology and pathology of cervical lesions; however, its diagnostic value remains poor (36). Instead, direct biopsy remains the gold standard for diagnosis. Nevertheless, invasive examinations may cause adverse psychological effects, including anxiety, depression or distress (37). Surgery, chemotherapy and radiotherapy (38) are the three major therapeutic strategies in the treatment of CC; however, their uses may be limited for various reasons. Surgery may be limited by the status and stage of patients, including late stage or tolerance to anesthesia (39), whereas chemotherapy is limited due to the lack of sensitivity and the development of drug resistance (40). In addition, radiotherapy can be limited by the maximum tolerated dose to adjacent normal tissues (41). Thus, it is essential to understand the underlying molecular mechanisms in the initiation and development of CC, in order to develop methods for its accurate diagnosis and effective treatment. A number of studies have reported that multiple genes [CXCL12 (42), FGFR4 (29) and SHH (43)], proteins [cyclin D1 (44), FOXO1 (45) and BASP1 (46)] and pathways [Toll-like signaling pathway (47), VEGF signaling pathway (48) and Wnt signaling pathway (30)] are involved in the natural progression of CC; however, few studies have investigated the fundamental pathological molecular mechanisms in the progression of CC (from normal, to CIN1, CIN2, CIN3, to cancer). Thus, the specific pathological processes remain unclear.

The present study provided a systematic investigation of the development of CC and further understanding of the associations between the four phases of CC progression, and thus revealed additional targets for the detection and treatment of CC. A flow diagram of the present study is presented in Fig. 1.

Materials and methods <sec> <title>Identification of differentially expressed genes (DEGs)

The CC gene expression profile in the GSE63514 dataset, acquired using the GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array) provided by den Boon in 2015 (49), was downloaded from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). The profile contained 128 cervical specimens, including: Normal (n=24), CIN1 (n=14), CIN2 (n=22), CIN3 (n=40) and cancer (n=28) samples. All samples were divided into four phases as follows: Phase I, normal to CIN1; phase II, CIN1 to CIN2; phase III, CIN2 to CIN3 and phase IV, CIN3 to cancer, and GEO2R tools (https://www.ncbi.nlm.nih.gov/geo/geo2r/) (50) within the limma package version 3.26.8 (51) were used to screen the DEGs at the four phases. The criteria fold change (FC) of expression >2 and P<0.05 were used to identify DEGs.

Identification of hub genes

The Search Tool for the Retrieval of Interacting Genes (STRING) database (52) and Cytoscape software (version 3.5.1) (53) were used to identify the hub genes in the four phases. The PPI network was constructed by searching for gene symbols and the minimum required interaction score was set at 0.7, to ensure high confidence in the results. The nodes that not connect to the major network were removed to decrease the error detection rate. CytoHubba (54), a plug-in for Cytoscape software, was used to investigate notable nodes in the interactome network using 12 topological algorithms, including Degree, Edge Percolated Component, Maximum Neighborhood Component, Density of Maximum Neighborhood Component and Maximal Clique Centrality, and centralities based on shortest paths, such as Bottleneck, EcCentricity, Closeness, Radiality, Betweenness, Clustering Coefficient and Stress. The genes that ranked in the top 10 for each topological algorithm were extracted and the duplication of each gene was calculated. Genes duplicated <2 times were excluded, in order to guarantee that the genes were associated with CC. The remaining genes were considered as hub genes in the four phases.

Functional enrichment analyses of GO and pathways

The functional features of the genes associated with the four phases were examined using WebGestalt (55) and ToppGene (56). In WebGestalt, over-representation analysis was selected as the enrichment method, Biological Process in GO as the functional database, gene symbol as the gene ID type and genome as the reference set for enrichment analysis. In ToppGene, two frequently used databases, Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.kegg.jp/) and BioCarta (https://www.biocarta.com/), were utilized to perform pathway enrichment analysis, to improve the reliability of the results. Pathways with a false discovery rate of P<0.05 were considered to indicate significantly enriched pathways.

Pathway crosstalk analysis

Pathway crosstalk analysis was performed (57), to investigate the interactions among the significantly enriched pathways. The pathways with either a false discovery rate of P>0.05 or <3 genes were removed as selection criteria. The number of shared genes between pairwise pathways was calculated and pairwise pathways with <2 overlapping genes were removed. The Jaccard Coefficient (JC) and the Overlap Coefficient (OC) parameters were calculated, to measure the overlap between the pathways. Specifically, JC=|A∩BA∪B|, while OC=|A∩Bmin(|A|,|B|)|, where A and B represent the gene numbers of the tested pathways. The interrelationships between pathways were visualized using Cytoscape software.

To determine the overall progression and further detect an association between two pathways, the KEGG and BioCarta databases were used to identify the upstream or downstream associations between pathways. Furthermore, the nodal degree was calculated using Centiscape (58) to identify key nodes. According to Han et al (59), key nodes are considered as those with a nodal degree ≥5.

Integration of the PPI network

The PPI network (60) was used to identify key proteins for the four phases of CC. As Protein Interaction Network Analysis (PINA) (https://omics.bjcancer.org/pina/) (61) is an integrated platform for protein interaction network construction, analysis and visualization, it can identify the associations between the queried genes based on integration of data from six public PPI databases: IntAct (62), MINT (63), BioGRID (64), DIP (65), HPRD (66) and MIPS MPact (67). Thus, the PINA4MS plug-in for Cytoscape software was used to construct the PPI network, to identify CC progression-associated genes. As PINA4MS requires UniProt accession numbers, the UniProt Retrieve/ID mapping tool (https://www.uniprot.org/uploadlists/) was used to input gene symbols. The key nodes for the PPI network were also extracted using a criterion of nodal degree ≥5.

Comprehensive gene-pathway analysis

To determine the molecular mechanisms and associations between the key genes and pathways, the gene-pathway network was constructed by examining the key pathways, in order to determine which pathway contained at least one of the key genes.

Co-expression and survival analysis for key genes

To identify the co-expression of key genes and their impact on OS time, the LinkedOmics database (68) was used, which was based on TCGA (69). The co-expression analysis was performed using Pearson correlation and OS analysis was assessed with Cox regression method. For survival analysis, samples were divided by the median value of the investigated gene. P<0.05 was considered to indicate a statistically significant difference for both the co-expression correlation and OS time.

Results <sec> <title>Identification of DEGs

Analysis of the GSE63514 dataset using GEO2R, with a criteria of ≥2 FC and P<0.05, identified a total of 3,446 DEGs for the four phases as follows: 446 DEGs in phase I, of which 76 were upregulated and 370 were downregulaged; 382 DEGs in phase II, of which 146 were upregulated and 236 were downregulated; 756 DEGs in phase III, of which 435 were upregulated and 321 were downregulated; 1,862 DEGs in phase IV, of which 816 were upregulated and 1046 were downregulated.

Identification of hub genes

Following removal of 2,256 irrelevant genes (Phase I, 265; Phase II, 197; Phase III, 603; Phase IV, 1191), 12 topological algorithms were used and the top 10 genes for each method were extracted. A total of 107 genes that appeared at least twice were conserved as hub genes, as presented in Table I. A total of 29 genes were identified in phase I, among which five genes were members of the kinesin family (KIF11, KIF15, KIF23, KIF4A and KIF14), and five genes were associated with meiosis and the maturation of oocytes [BUB1B (70), BUB1 (71), CCNA2 (72), CCNB1 (72) and CDK1 (73)], as well as other genes associated with inflammation and innate immune responses [STAT1 (74), GBP1 (75) and RHOA (76)]. A total of 25 hub genes were verified in phase II, among which the involvement of seven interferon-induced genes was identified (IFI44L, IFIT3, IFIF1, IFIF5, IFI44, IFIT2 and IFI6), and several pattern recognition receptor-associated genes [IRF7 (77), STAT1 (78) and CXCL10 (79)], as well as some genes involved in invasion and metastasis of cancer cells [HGF (80), IGF1 (81), KIT (82), FN1 (83) and CXCL12 (84)]. A number of common cancer-associated signaling pathway genes were identified in phase III [CCND1 (85), STAT1 (86) and VEGFA (87)]. A total of three C-X-C motif chemokine ligands (CXCL8, CXCL11 and CXCL4), two integrin subunits (ITGB1 and ITGA1), and one mitogen-activated protein (MAPK12) were identified in phase IV. Furthermore, PIK3CA (88) and FOS (89) participated in cancer-associated pathways in phase IV. The diversity of genes within the four phases demonstrated that CC progression is a complex process and its molecular mechanisms are not constant.

GO enrichment analysis of hub genes

To further identify the biological functions and locations of hub genes, GO enrichment analysis (90) was performed (Fig. 2). Hub genes were notably enriched in ‘biological regulation’, ‘metabolic process’ and ‘cellular component organization’ in phase I and II, while ‘responses to stimulus’ and ‘biological regulation’ were predominantly enriched at phases III–IV in biological process. For the cellular components, ‘nucleus’, ‘membrane-enclosed lumen’ and ‘macromolecular complex’ was enriched at phases I–III, while ‘chromosome’ and ‘membrane’ was identified in phases II and IV, respectively. ‘Protein binding’ was enriched at all four phases for Molecular Function. Furthermore, ‘nucleic acid binding’ and ‘hydrolase activity’ were enriched at phase II and III, while ‘ion binding’ was enriched at phase III and IV.

Pathway enrichment analysis of hub genes

As presented in Table II, a total of 10 notably enriched pathways were identified at phase I, of which five pathways were associated with virus infections including, ‘influenza A’, ‘tuberculosis’, ‘herpes simplex infection’, ‘viral carcinogenesis’ and ‘Epstein-Barr virus infection’, and additional pathways involved in the ‘cell cycle’, ‘oocyte meiosis’ and ‘progesterone-mediated oocyte maturation’. Furthermore, the chemokine signaling pathway was also identified in phase I. The RIG-I-like receptor and Toll-like receptor signaling pathways were identified in phase II, and are associated with pattern-recognition receptors (91). In addition, several pathways, including ‘focal adhesion’, ‘Rap1 signaling pathway’, ‘Ras signaling pathway’, ‘PI3K-Akt signaling pathway’ and ‘Proteoglycans in cancer’ were associated with invasion and metastasis (92–96). The two common cancer-associated signaling pathways ‘Pathways in cancer’ and ‘Proteoglycans in cancer’, were enriched in phase III, while 70 pathways were significant enriched at phase IV (P<0.05). Apart from the common cancer-associated signaling pathways and virus infection pathways at phase IV, the ‘IL-17 signaling pathway’, ‘VEGF signaling pathway’ and ‘endocrine resistance’ also were also demonstrated to be associated with CC progression. Furthermore, the ‘AGE-RAGE signaling pathway in diabetic complications’ was also identified at phases II–IV.

Pathway crosstalk analysis

The pathway crosstalk analysis results are presented in Fig. S1. A total of two major modules were identified in phase I, one of which was predominantly associated with inflammatory responses to viral infections, such as the NOD-like receptor signaling pathway and the chemokine signaling pathway, while the other module was associated with cycle regulation of oocytes, including cell cycle, progesterone-mediated oocyte maturation and oocyte meiosis (Fig. S1A). Similarly, the pathways were grouped into two modules in phase II. One module consisted of immune responses (RIG-I-like receptor and Toll-like receptor signaling pathways, and NOD-like receptor signaling pathway), which may trigger rapid activation of innate immunity by inducing the production of proinflammatory cytokines (97–99). The other module was predominantly involved in the regulation of cell proliferation and invasion (Ras signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, focal adhesion and other cancer-associated signaling pathways) (Fig. S1B). Notably, the two modules in phases I and II were not independent as they were demonstrated to connect with each other via several signaling pathways. All pathways formed a cluster and common cancer-associated signaling pathways were indicated to play a critical role in phase III (Fig. S1C), while the connection between the pathways became highly complex in phase IV (Fig. S1D). The possible molecular mechanisms, such as inflammation caused by virus infections, pathways associated with cell invasion, IL-17 and VEGF signaling pathways, and endocrine resistance, are associated with one another. These results further verified the complexity of CC. A comprehensive combination of pathway crosstalk analysis containing 47 nodes and 105 edges among the four phases is presented in Fig. 3A. By analyzing the nodes with degrees ≥5, a subnetwork containing 11 key pathways was extracted (Fig. 3B). It indicates that the MAPK signaling pathway (degree=33), PI3K-Akt signaling pathway (degree=21) and focal adhesion (degree=15), which are ranked as the top three nodes and most interactive, may play critical roles in the progression of CC.

PPI network analysis

A PPI network containing 51 nodes and 78 edges was constructed (Fig. 4A) by downloading the hub genes into the PINA database. Based on the description of a previous study (59), which defined the main nodes as nodes with degree >5, 14 key genes were identified from the PPI network (Fig. 4B). CDK1, FN1 and ITGB1 rank first, second and third, respectively, as the top three-degree levels (16, 12 and 8, respectively). STAT1 was the only gene demonstrated to be involved at all four phases. Furthermore, MMP9 presented self-regulating functions and was demonstrated to co-express with FN1 and ITGB1.

Comprehensive gene-pathway analysis

After mapping the key genes onto the key pathways using the KEGG and BioCarta databases, a potential gene-pathway flowchart, including eight key pathways and six key genes was constructed (Fig. 5). The results demonstrated the following: For phase I, CDK1 and CCNB1 participated in the regulation of the cell cycle, while CDK1 was also involved in viral carcinogenesis; for phases II–IV, ‘pathways in cancer,’ ‘focal adhesion’ and ‘PI3K-Akt signaling pathway’ were ranked the top three pathways according to the number of genes involved; FN1, ITGB1 and MMP9 may be associated with metastasis of tumor cells, and STAT1 participated in ‘pathways in cancer’ and ‘Toll-like receptor signaling pathway’, which functioned at a phase IV.

Co-expression network and survival analysis for key genes

By mining the data from LinkedOmics, the results of co-expression demonstrated that CDK1 had a significantly positive correlation with CCNB1 (P<0.0001), but negative correlation with FN1 (P=0.003) and MMP9 (P=0.001), respectively (Fig. 6). CCNB1 demonstrated a significantly negative correlation with ITGB1 (P=0.047); however, FN1, ITGB1 and MMP9 indicated a significantly positive correlation between each other (FN1 and ITGB1, P<0.001; FN1 and MMP9, P<0.0001; ITGB1 and MMP9, P=0.023). STAT1 was significantly positively correlated with MMP9 (P<0.0001).

Survival analysis indicated that patients with higher FN1 and ITGB1 expression levels had a significantly worse OS time (FN1, P=0.00080; ITGB1, P=0.00005; Fig. 7). However, CDK1, CCNB1, MMP9 and STAT1 were not demonstrated to have a significant effect on OS.

Discussion

To date, the occurrence and development of CC is hypothesized to be linked with persistent HPV infection (100); however, the specific molecular mechanisms require further investigation. In addition, although a number of studies are examining the molecular mechanisms of CC (101–104), the detailed pathological process remains unclear.

The results of the present study indicated that CDK1 had the highest degree, and participated in the cell cycle with CCNB1 and viral carcinogenesis in phase I. CDK1 is one of the major cell cycle regulatory proteins and operates at the center of the cell cycle regulatory network (105). It regulates the G-S phase transition and initiates DNA replication (106). Furthermore, as a core molecule at the M phase checkpoint, CDK1 plays a role in the regulation of G₂ phase, at M phase in the cell cycle (107). The HPV infection pathway is regulated within the viral carcinogenesis pathway (19). E6 proteins inactivate p53 by binding (108), while p53 negatively regulates CDK1 transcription under normal physiological conditions (109). In addition, the activation of cyclin B1-CDK1 is the key event that initiates the start of mitosis (110). Centrosome separation can be regulated by CDK1 (111), and cyclin B1-CDK1 remains activated following centrosome separation (110). Hence, overexpression of CDK1 can cause dysfunction in cell cycle progression, failure of normal proliferation and differentiation, and thereby lead to malignant proliferation of cancer cells and the formation of CC. CCNB1 is a notable member of the cyclin family, a key initiator and a stringent quality control step of mitosis (112). It also plays a key role in the regulation of CDK1, and its phosphorylated substrates can promote the transition of the cell cycle from G₂ to mitosis (113,114). Amplification of the HPV genome depends on prolongation of the G₂ phase in the cell cycle (115). CCNB1 is a downstream target of STAT3, which is a key gene that regulates the proliferation and differentiation of CC cells (116). In cells with inactivated STAT3, CCNB1 expression is downregulated and amplification of the HPV genome is also decreased, resulting in decreased activity of CC cells (116). As the results of the present study demonstrated that CDK1 and CCNB1 occurred in phase I and functioned as regulators of proliferation and differentiation, they may be potential promoters of CIN and CC.

In the process of tumor invasion and metastasis, cancer cells can bind to ligands of the extracellular matrix (ECM) via integrins and degrade the basement membrane (BM) by secreting proteases via the pathways of focal adhesion and the PI3K-Akt signaling pathway (117). This degradation is also the prerequisite for stromal infiltration and cancer cell migration (118). ITGB1 belongs to the integrin family and FN1 is the ligand. The binding of ITGB1 and FN1 induces the phosphorylation of tyrosine and directly affects cytoskeleton reconstruction and signal transduction activities of the Ras-MAPK signaling pathway via the RAP1 signaling pathway, which initiates the expression of MMP genes (119). MMPs are a family of calcium and zinc-dependent proteases that degrade a variety of components of the ECM (120). Collagen type IV is the main scaffold in the BM of the ECM and also the main substrate of MMP9 (121). MMP9 can decompose the nestin in the BM to destroy the cells integrity and promote the invasion and metastasis of cancer cells (122). MMP9 expression in HPV-positive patients with CC is higher than in HPV-negative patients (123). Cardeal et al (124) reported that MMP9 is upregulated in human keratinocytes expressing the HPV16 E7 protein. This may be due to TIMP2, an inhibitor of MMP9, which could be downregulated by HPV16 E7. It was also demonstrated that HPV can directly regulate the activity of MMP9 in lung cancer cells (125). There may be an association between HPV infection and the MMP family, which may be beneficial in the diagnosis of cervical precancerous lesions and CC as MMP9 may be considered as a novel biomarker. However, the specific molecular mechanisms require further investigation. As FN1 and ITGB1 were targets of miR-9-3p (126) and FN1 promoted migration and invasion by upregulating MMP9 in cancer (127), it is not surprising that these three genes are co-expressed as a reaction triplet. Furthermore, since higher levels of FN1 and ITGB1 are significantly associated with lower OS rate, these two genes may be developed as novel prognostic factors for CC.

STAT1, the only gene that participates in all four phases, in the present study, is involved in the cancer pathway at phases II, III and IV. It has been reported that STAT1 is upregulated in both CIN1 and CC (128), and the results of the present study that STAT1 is upregulated in phase I, III and IV confirmed this finding. A previous study demonstrated that activated STAT1 plays a tumor suppressive role in breast cancer cells (129). Nevertheless, STAT1 also exerts tumor promoter effects under specific conditions (130). In some malignant diseases, including breast and lung cancers, STAT1 can act as an oncoprotein or a tumor suppressor of the same cell type based on the specific genetic background (130). In CC, STAT1 may have a protective effect in the early stages of HPV infection but may act as a proto-oncogene during the invasive phase of the disease (128). STAT1 can promote cancer cell death by activating p53 expression, and it plays a role in immunosurveillance, and the inhibition of angiogenesis and metastasis in cancer cells (130); however, STAT1 can also promote tumor invasion and metastasis in chronic inflammation (131). The effect of STAT1 in CC still remains unclear; therefore, further verification is required as it may be a key target for the treatment of CC.

The current study presented several limitations. First, as this was an in-silico study, the identification of DEGs may change with additional data, thus the results of subsequent analyses may change accordingly. Secondly, some genes were excluded to decrease the false-positive rate; however, these genes may also have a vital effect on CC. Thirdly, although several genes associated with HPV infection (TP53TG1, RAC1, PAK2 and LTBP2) were identified in DEGs, HPV infection was not observed in the pathway analyses. This may be due to the fact that an insufficient amount of hub genes were identified, or the genes had a low or moderate effect on the HPV infection pathway.

In conclusion, the present study revealed that CDK1, CCNB1, ITGB1, FN1, MMP9 and STAT1 played different roles in the progression of CC through different signaling pathways. CDK1 and CCNB1 served as regulators of proliferation and differentiation via regulation of the cell cycle and viral tumorigenesis, and initiated CIN and CC, whereas FN1, ITGB1 and MMP9 were co-expressed as a reaction triplet to trigger metastasis via cancer pathways, PI3K-Akt signaling pathway and focal adhesion. FN1 and ITGB1 may be novel prognostic factors for CC. STAT1 may have a protective effect in the early stage of HPV infection, but may also act as a proto-oncogene during the invasive stage; however, the specific molecular mechanisms require further investigation.

Supplementary Material

Supporting Data

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated and/or analyzed during this study are included in this published article. The datasets generated and/or analyzed during the current study are available in the GEO (https://www.ncbi.nlm.nih.gov/geo/) and LinkOmics (http://www.linkedomics.org/) repository.

Authors' contributions

YY, YF and WZ designed the present study and drafted the initial manuscript. KW and YL performed the literature review, acquired the data and performed the statistical analyses. All authors have read and approved the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

cervical cancer

CIN

cervical intraepithelial neoplasia

Gene Ontology

PPI

protein-protein interaction

TCGA

The Cancer Genome Atlas

DEG

differentially expressed gene

overall survival

STRING

Search Tool for the Retrieval of Interacting Genes

KEGG

Kyoto Encyclopedia of Genes and Genomes

jaccard coefficient

overlap coefficient

PINA

protein interaction network analysis

References 1

Bray

Ferlay

Soerjomataram

Siegel

Torre

Jemal

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

CA Cancer J Clin683944242018

10.3322/caac.21492

30207593

Muliira

Salas

O'Brien

Quality of life among female cancer survivors in Africa: An integrative literature review

Asia Pac J Oncol Nurs46172017

10.4103/2347-5625.199078

28217724

Gravitt

Winer

Natural history of HPV infection across the lifespan: Role of viral latency

Viruses9E2672017

10.3390/v9100267

28934151

Walboomers

Jacobs

Manos

Bosch

Kummer

Shah

Snijders

Peto

Meijer

Muñoz

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

J Pathol18912191999

10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

10451482

Louie

de Sanjose

Diaz

Castellsagué

Herrero

Meijer

Shah

Franceschi

Muñoz

Bosch

International Agency for Research on Cancer Multicenter Cervical Cancer Study Group

Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries

Br J Cancer100119111972009

10.1038/sj.bjc.6604974

19277042

Liu

Chen

Multiple sexual partners as a potential independent risk factor for cervical cancer: A meta-analysis of epidemiological studies

Asian Pac J Cancer Prev16389339002015

10.7314/APJCP.2015.16.9.3893

25987056

Smith

Green

Berrington de Gonzalez

Appleby

Peto

Plummer

Franceschi

Beral

Cervical cancer and use of hormonal contraceptives: A systematic review

Lancet361115911672003

10.1016/S0140-6736(03)12949-2

12686037

Wei

Lin

Lung

Chang

Whang-Peng

Liu

Yang

Shen

PIK3CA as an oncogene in cervical cancer

Oncogene19273927442000

10.1038/sj.onc.1203597

10851074

Zheng

Zhang

Guo

Yao

Dou

Guo

Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer

Oncol Rep33233723442015

10.3892/or.2015.3867

25813398

Bai

Wang

Zhao

Wen

Guo

Shen

Yang

LncRNA CRNDE acts as an oncogene in cervical cancer through sponging miR-183 to regulate CCNB1 expression

CarcinogenesisOct122019(Epub ahead of print)

Bremer

Tieboschb

van der Putten

de Haan

Arends

p53 tumor suppressor gene protein expression in cervical cancer: Relationship to prognosis

Eur J Obstet Gynecol Reprod Biol6355591995

10.1016/0301-2115(95)02225-V

8674566

Cohen

Singer

Lavie

Dong

Beller

Sidransky

The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix

Clin Cancer Res9298129842003

12912945

Hasina

Pontier

Fekete

Martin

Brigaudeau

Pramanik

Cline

Coignet

Lingen

NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype

Oncogene255885982006

10.1038/sj.onc.1209070

16205646

Roura

Castellsagué

Pawlita

Travier

Waterboer

Margall

Bosch

de Sanjosé

Dillner

Gram

Smoking as a major risk factor for cervical cancer and pre-cancer: Results from the EPIC cohort

Int J cancer1354534662014

10.1002/ijc.28666

24338632

Husain

Ramakrishnan

Global variation of human papillomavirus genotypes and selected genes involved in cervical malignancies

Ann Glob Health816756832015

10.1016/j.aogh.2015.08.026

27036725

Soto

Song

McLaughlin-Drubin

Epigenetic alterations in human papillomavirus-associated cancers

Viruses9E2482017

10.3390/v9090248

28862667

Mincheva

Gissmann

zur Hausen

Chromosomal integration sites of human papillomavirus DNA in three cervical cancer cell lines mapped by in situ hybridization

Med Microbiol Immunol1762452561987

10.1007/BF00190531

2821369

Senapati

Dwibedi

Molecular mechanisms of HPV mediated neoplastic progression

Infect Agent Cancer11592016

10.1186/s13027-016-0107-4

27933097

Münger

Baldwin

Edwards

Hayakawa

Nguyen

Owens

Grace

Huh

Mechanisms of human papillomavirus-induced oncogenesis

J Virol7811451114602004

10.1128/JVI.78.21.11451-11460.2004

15479788

Martinez-Zapien

Ruiz

Poirson

Mitschler

Ramirez

Forster

Cousido-Siah

Masson

Vande Pol

Podjarny

Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53

Nature5295415452016

10.1038/nature16481

26789255

Scheffner

Huibregtse

Vierstra

Howley

The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53

Cell754955051993

10.1016/0092-8674(93)90384-3

8221889

Sherr

The Pezcoller lecture: Cancer cell cycles revisited

Cancer Res60368936952000

10919634

Martin

Demers

Galloway

Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E

J Virol729759851998

10.1128/JVI.72.2.975-985.1998

9444990

Löffler

Fechter

Matuszewska

Saffrich

Mistrik

Marhold

Hornung

Westermann

Bartek

Krämer

Cep63 recruits Cdk1 to the centrosome: Implications for regulation of mitotic entry, centrosome amplification, and genome maintenance

Cancer Res71212921392011

10.1158/0008-5472.CAN-10-2684

21406398

Skyldberg

Fujioka

Hellström

Sylvén

Moberger

Auer

Human papillomavirus infection, centrosome aberration, and genetic stability in cervical lesions

Mod Pathol142792842001

10.1038/modpathol.3880303

11301343

Duensing

Münger

The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability

Cancer Res62707570822002

12460929

Chaiwongkot

Niruthisard

Kitkumthorn

Bhattarakosol

Quantitative methylation analysis of human papillomavirus 16 L1 gene reveals potential biomarker for cervical cancer progression

Diagn Microbiol Infect Dis892652702017

10.1016/j.diagmicrobio.2017.08.010

28985972

Sharma

Javed

Srinivasan

Pal

Bhattacharyya

Sonic hedgehog pathway activation regulates cervical cancer stem cell characteristics during epithelial to mesenchymal transition

J Cell PhysiolFeb42019(Epub ahead of print)

10.1002/jcp.28231

Zhang

Zou

Association between FGFR4 gene polymorphism and high-risk HPV infection cervical cancer

Asian Pac J Trop Med106806842017

10.1016/j.apjtm.2017.07.008

28870344

Zhang

Gao

CCAT-1 promotes proliferation and inhibits apoptosis of cervical cancer cells via the Wnt signaling pathway

Oncotarget868059680702017

28978096

Mora-García

Ávila-Ibarra

García-Rocha

Weiss-Steider

Hernández-Montes

Don-López

Gutiérrez-Serrano

Titla-Vilchis

Fuentes-Castañeda

Monroy-Mora

Cervical cancer cells suppress effector functions of cytotoxic T cells through the adenosinergic pathway

Cell Immunol32046552017

10.1016/j.cellimm.2017.09.002

28950987

Song

Ding

Ren

Sun

Yang

Wang

Feng

Liu

Wang

Effects of Src on cervical cancer cells proliferation and apoptosis through ERK signal transduction pathway

Zhonghua Liu Xing Bing Xue Za Zhi38124612512017(In Chinese; Abstract available in Chinese from the publisher)

28910941

Zhou

Shi

Cao

Dinh

TLA

Wan

Zhao

Investigation of differentially-expressed microRNAs and genes in cervical cancer using an integrated bioinformatics analysis

Oncol Lett13278427902017

10.3892/ol.2017.5766

28454467

Chen

Zheng

Screening for cervical cancer-related genes and their bioinformatics analysis

Nan Fang Yi Ke Da Xue Xue Bao285855882008(In Chinese)

18495597

Nayar

Wilbur

The bethesda system for reporting cervical cytology: A historical perspective

Acta Cytol613593722017

10.1159/000477556

28693017

Shoji

Takatori

Takeuchi

Yoshizaki

Uesugi

Sugai

Sugiyama

Clinical significance of atypical glandular cells in the bethesda system 2001: A comparison with the histopathological diagnosis of surgically resected specimens

Cancer Invest321051092014

10.3109/07357907.2014.880453

24576221

O'Connor

Gallagher

Waller

Martin

O'Leary

Sharp

Irish Cervical Screening Research Consortium (CERVIVA)

Adverse psychological outcomes following colposcopy and related procedures: A systematic review

BJOG12324382016

10.1111/1471-0528.13462

26099164

Haque

Uddin

AFMK

Dey

Islam

Goodman

Challenges to cervical cancer treatment in Bangladesh: The development of a women's cancer ward at Dhaka Medical College Hospital

Gynecol Oncol Rep2167722017

10.1016/j.gore.2017.06.001

28725676

Roque

Wysham

Soper

The surgical management of cervical cancer: An overview and literature review

Obstet Gynecol Surv694264412014

10.1097/OGX.0000000000000089

25112591

Marin

Romero

Blazquez

Herraez

Keck

Briz

Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours

Anticancer Agents Med Chem91621842009

10.2174/187152009787313828

19199863

Chen

HHW

Kuo

Improving radiotherapy in cancer treatment: Promises and challenges

Oncotarget862742627582017

28977985

Lecavalier-Barsoum

Chaudary

Han

Pintilie

Hill

Milosevic

Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy

Br J Cancer1212492562019

10.1038/s41416-019-0545-z

31239542

Zhang

Ren

Liu

Chen

Yang

Zhang

Wang

SHH gene silencing suppresses epithelial-mesenchymal transition, proliferation, invasion, and migration of cervical cancer cells by repressing the hedgehog signaling pathway

J Cell Biochem119382938422018

10.1002/jcb.26414

28941302

Zhang

Yang

Wang

Expression of cyclin D1 protein isoforms and its prognostic significance in cervical cancer

Cancer Manag Res11907390832019

10.2147/CMAR.S224026

31695498

Chay

Han

Nam

Cho

Chung

Hewitt

Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer

Int J Clin Oncol24142914392019

10.1007/s10147-019-01507-w

31302815

Tang

Wang

Zhang

Xiong

Liu

Chen

Tan

High brain acid soluble protein 1(BASP1) is a poor prognostic factor for cervical cancer and promotes tumor growth

Cancer Cell Int17972017

10.1186/s12935-017-0452-4

29089860

Yang

Cheng

The role of TLRs in cervical cancer with HPV infection: A review

Signal Transduct Target Ther2170552017

10.1038/sigtrans.2017.55

29263932

Frumovitz

Sood

Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies

Gynecol Oncol1047687782007

10.1016/j.ygyno.2006.10.062

17306693

den Boon

Pyeon

Wang

Horswill

Schiffman

Sherman

Zuna

Wang

Hewitt

Pearson

Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling

Proc Natl Acad Sci USA112E3255E32642015

10.1073/pnas.1509322112

26056290

Barrett

Wilhite

Ledoux

Evangelista

Kim

Tomashevsky

Marshall

Phillippy

Sherman

Holko

NCBI GEO: Archive for functional genomics data sets-update

Nucleic Acids Res41D991D9952013

10.1093/nar/gks1193

23193258

Ritchie

Phipson

Law

Shi

Smyth

Limma powers differential expression analyses for RNA-sequencing and microarray studies

Nucleic Acids Res43e472015

10.1093/nar/gkv007

25605792

Szklarczyk

Franceschini

Wyder

Forslund

Heller

Huerta-Cepas

Simonovic

Roth

Santos

Tsafou

STRING v10: Protein-protein interaction networks, integrated over the tree of life

Nucleic Acids Res43D447D4522015

10.1093/nar/gku1003

25352553

Shannon

Markiel

Ozier

Baliga

Wang

Ramage

Amin

Schwikowski

Ideker

Cytoscape: A software environment for integrated models of biomolecular interaction networks

Genome Res13249825042003

10.1101/gr.1239303

14597658

Chin

Chen

Lin

cytoHubba: Identifying hub objects and sub-networks from complex interactome

BMC Syst Biol8(Suppl 4)S112014

10.1186/1752-0509-8-S4-S11

25521941

Wang

Vasaikar

Shi

Greer

Zhang

WebGestalt 2017: A more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit

Nucleic Acids Res45W130W1372017

10.1093/nar/gkx356

28472511

Chen

Bardes

Aronow

Jegga

ToppGene Suite for gene list enrichment analysis and candidate gene prioritization

Nucleic Acids Res37W305W3112009

10.1093/nar/gkp427

19465376

Pan

Zhang

Wang

Network and pathway-based analyses of genes associated with Parkinson's disease

Mol Neurobiol54445244652017

10.1007/s12035-016-9998-8

27349437

Scardoni

Petterlini

Laudanna

Analyzing biological network parameters with CentiScaPe

Bioinformatics25285728592009

10.1093/bioinformatics/btp517

19729372

Han

Berlin

Hao

Goldberg

Berriz

Zhang

Dupuy

Walhout

Cusick

Roth

Vidal

Evidence for dynamically organized modularity in the yeast protein-protein interaction network

Nature43088932004

10.1038/nature02555

15190252

Kanwal

Fazal

Construction and analysis of protein-protein interaction network correlated with ankylosing spondylitis

Gene63841512018

10.1016/j.gene.2017.09.049

28966133

Vallenius

Ovaska

Westermarck

Mäkelä

Hautaniemi

Integrated network analysis platform for protein-protein interactions

Nat Methods675772009

10.1038/nmeth.1282

19079255

Kerrien

Alam-Faruque

Aranda

Bancarz

Bridge

Derow

Dimmer

Feuermann

Friedrichsen

Huntley

IntAct-source resource for molecular interaction data

Nucleic Acids Res35D561D5652007

10.1093/nar/gkl958

17145710

Chatr-aryamontri

Ceol

Palazzi

Nardelli

Schneider

Castagnoli

Cesareni

MINT: The Molecular INTeraction database

Nucleic Acids Res35D572D5742007

10.1093/nar/gkl950

17135203

Breitkreutz

Stark

Reguly

Boucher

Breitkreutz

Livstone

Oughtred

Lackner

Bähler

Wood

The BioGRID interaction database: 2008 update

Nucleic Acids Res36D637D6402008

10.1093/nar/gkm1001

18000002

Salwinski

Miller

Smith

Pettit

Bowie

Eisenberg

The database of interacting proteins: 2004 update

Nucleic Acids Res32D449D4512004

10.1093/nar/gkh086

14681454

Peri

Navarro

Amanchy

Kristiansen

Jonnalagadda

Surendranath

Niranjan

Muthusamy

Gandhi

Gronborg

Development of human protein reference database as an initial platform for approaching systems biology in humans

Genome Res13236323712003

10.1101/gr.1680803

14525934

Güldener

Münsterkötter

Oesterheld

Pagel

Ruepp

Mewes

Stümpflen

MPact: The MIPS protein interaction resource on yeast

Nucleic Acids Res34D436D4412006

10.1093/nar/gkj003

16381906

Vasaikar

Straub

Wang

Zhang

LinkedOmics: Analyzing multi-omics data within and across 32 cancer types

Nucleic Acids Res46D956D9632018

10.1093/nar/gkx1090

29136207

Cancer Genome Atlas Research NetworkWeinstein

Collisson

Mills

Shaw

Ozenberger

Ellrott

Shmulevich

Sander

Stuart

The cancer genome atlas pan-cancer analysis project

Nat Genet45111311202013

10.1038/ng.2764

24071849

Gasca

Pellestor

Assou

Loup

Anahory

Dechaud

De Vos

Hamamah

Identifying new human oocyte marker genes: A microarray approach

Reprod Biomed Online141751832007

10.1016/S1472-6483(10)60785-7

17298719

Schwab

Roberts

Gross

Tunquist

Taieb

Lewellyn

Maller

Bub1 is activated by the protein kinase p90(Rsk) during Xenopus oocyte maturation

Curr Biol111411502001

10.1016/S0960-9822(01)00045-8

11231148

Ouandaogo

Frydman

Hesters

Assou

Haouzi

Dechaud

Frydman

Hamamah

Differences in transcriptomic profiles of human cumulus cells isolated from oocytes at GV, MI and MII stages after in vivo and in vitro oocyte maturation

Hum Reprod27243824472012

10.1093/humrep/des172

22617121

Qian

Sun

Cyclins regulating oocyte meiotic cell cycle progression†

Biol Reprod1018788812019

10.1093/biolre/ioz143

31347666

Kaplan

STAT signaling in inflammation

JAKSTAT2e241982013

24058801

Qiu

Guo

Yang

Chen

Down-regulation of guanylate binding protein 1 causes mitochondrial dysfunction and cellular senescence in macrophages

Sci Rep816792018

10.1038/s41598-018-19828-7

29374208

Bros

Haas

Moll

Grabbe

RhoA as a key regulator of innate and adaptive immunity

Cells8E7332019

10.3390/cells8070733

31319592

Erdely

Antonini

Salmen-Muniz

Liston

Hulderman

Simeonova

Kashon

Stone

Type I interferon and pattern recognition receptor signaling following particulate matter inhalation

Part Fibre Toxicol9252012

10.1186/1743-8977-9-25

22776377

Luu

Greenhill

Majoros

Decker

Jenkins

Mansell

STAT1 plays a role in TLR signal transduction and inflammatory responses

Immunol Cell Biol927617692014

10.1038/icb.2014.51

25027037

Smolen

Ruck

Fortuno

IIIHo

Dimitriu

Mohn

Speert

Cooper

Esser

Goetghebuer

Pattern recognition receptor-mediated cytokine response in infants across 4 continents

J Allergy Clin Immunol133818826.e42014

10.1016/j.jaci.2013.09.038

24290283

Xiang

Chen

HGF/Met signaling in cancer invasion: The impact on cytoskeleton remodeling

Cancers (Basel)9E442017

10.3390/cancers9050044

28475121

Lei

Ling

IGF-1 promotes the growth and metastasis of hepatocellular carcinoma via the inhibition of proteasome-mediated cathepsin B degradation

World J Gastroenterol2110137101492015

10.3748/wjg.v21.i35.10137

26401078

Cho

Kitadai

Yoshida

Tanaka

Yoshihara

Yoshida

Chayama

Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach

Int J Oncol28136113672006

16685437

Shen

Peng

Chen

Zheng

Jia

Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT

Onco Targets Ther12320732212019

10.2147/OTT.S195703

31118673

Liu

Ren

Yang

Chen

Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro

J Cell Physiol234389739092019

10.1002/jcp.27163

30191987

Chen

Jiang

Zhao

Luo

Liang

Zhen

Deng

Lin

microRNA-374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway

Oncotarget741306413192016

27191497

Thomas

Snowden

Zeidler

Danson

The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

Br J Cancer1133653712015

10.1038/bjc.2015.233

26151455

Stacker

Achen

The VEGF signaling pathway in cancer: The road ahead

Chin J Cancer322973022013

23419196

Shi

Wang

Lei

Cong

Tan

Zhou

Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review)

Mol Med Rep19452945352019

30942405

Jiang

Tapping

Toll-like receptor signaling in cell proliferation and survival

Cytokine49192010

10.1016/j.cyto.2009.08.010

19775907

Gene Ontology

Consortium

Gene ontology consortium: Going forward

Nucleic Acids Res43D1049D10562015

10.1093/nar/gku1179

25428369

Kawai

Akira

Toll-like receptor and RIG-1-like receptor signaling

Ann N Y Acad Sci11431202008

10.1196/annals.1443.020

19076341

Gkretsi

Stylianopoulos

Cell adhesion and matrix stiffness: Coordinating cancer cell invasion and metastasis

Front Oncol81452018

10.3389/fonc.2018.00145

29780748

Zhang

Wang

Cheng

Ring

Roles of Rap1 signaling in tumor cell migration and invasion

Cancer Biol Med1490992017

10.20892/j.issn.2095-3941.2016.0086

28443208

Campbell

Der

Oncogenic Ras and its role in tumor cell invasion and metastasis

Semin Cancer Biol141051142004

10.1016/j.semcancer.2003.09.015

15018894

Sun

Wang

Sun

Gao

Zhang

Sun

Tian

Zhao

Interleukin-8 promotes integrin β3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma

J Exp Clin Cancer Res384492019

10.1186/s13046-019-1455-x

31684995

Sanderson

Heparan sulfate proteoglycans in invasion and metastasis

Semin Cell Dev Biol1289982001

10.1006/scdb.2000.0241

11292374

Loo

Gale

Immune signaling by RIG-I-like receptors

Immunity346806922011

10.1016/j.immuni.2011.05.003

21616437

Nyati

Prasad

Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome

Mediators Inflamm20147586392014

10.1155/2014/758639

25614713

Saxena

Yeretssian

NOD-Like receptors: Master regulators of inflammation and cancer

Front Immunol53272014

10.3389/fimmu.2014.00327

25071785

100

Crosbie

Einstein

Franceschi

Kitchener

Human papillomavirus and cervical cancer

Lancet3828898992013

10.1016/S0140-6736(13)60022-7

23618600

101

Balasubramaniam

Balakrishnan

Oon

Kaur

Key molecular events in cervical cancer development

Medicina (Kaunas)55E3842019

10.3390/medicina55070384

31319555

102

Lin

Zhou

Wang

Zhu

Recent advances on the molecular mechanism of cervical carcinogenesis based on systems biology technologies

Comput Struct Biotechnol J172412502019

10.1016/j.csbj.2019.02.001

30847042

103

Yin

Xie

Huang

Zhou

Antiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro

Onco Targets Ther8121112182015

26060406

104

Yugawa

Kiyono

Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: Novel functions of E6 and E7 oncoproteins

Rev Med Virol19971132009

10.1002/rmv.605

19156753

105

Jones

Askari

Humphries

Cell adhesion is regulated by CDK1 during the cell cycle

J Cell Biol217320332182018

10.1083/jcb.201802088

29930204

106

Hochegger

Dejsuphong

Sonoda

Saberi

Rajendra

Kirk

Hunt

Takeda

An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells

J Cell Biol1782572682007

10.1083/jcb.200702034

17635936

107

Vassilev

Cell cycle synchronization at the G2/M phase border by reversible inhibition of CDK1

Cell Cycle5255525562006

10.4161/cc.5.22.3463

17172841

108

Shaikh

Sanehi

Rawal

Molecular screening of compounds to the predicted protein-protein interaction site of Rb1-E7 with p53-E6 in HPV

Bioinformation86076122012

10.6026/97320630008607

22829740

109

Yun

Chae

Choy

Chung

Yoo

Han

Shin

p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor

J Biol Chem27429677296821999

10.1074/jbc.274.42.29677

10514438

110

Lindqvist

van Zon

Karlsson Rosenthal

Wolthuis

Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression

PLoS Biol5e1232007

10.1371/journal.pbio.0050123

17472438

111

Crasta

Huang

Morgan

Winey

Surana

Cdk1 regulates centrosome separation by restraining proteolysis of microtubule-associated proteins

EMBO J25255125632006

10.1038/sj.emboj.7601136

16688214

112

Fang

Liang

Cai

Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer

Cancer Biol Ther15126812792014

10.4161/cbt.29691

24971465

113

Krek

Nigg

Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: Identification of major phosphorylation sites

EMBO J103053161991

10.1002/j.1460-2075.1991.tb07951.x

1846803

114

Morgan

Principles of CDK regulation

Nature3741311341995

10.1038/374131a0

7877684

115

Banerjee

Wang

Broker

Chow

Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes

J Biol Chem28615473154822011

10.1074/jbc.M110.197574

21321122

116

Morgan

Wasson

Hanson

Kealy

Pentland

McGuire

Scarpini

Coleman

Arthur

JSC

Parish

STAT3 activation by E6 is essential for the differentiation-dependent HPV18 life cycle

PLoS Pathog14e10069752018

10.1371/journal.ppat.1006975

29630659

117

Stewart

Cooper

Sikes

Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer

Reprod Biol Endocrinol222004

10.1186/1477-7827-2-2

14711377

118

Chiu

Peng

Hung

Lee

Liang

Raf activation by Ras and promotion of cellular metastasis require phosphorylation of prohibitin in the raft domain of the plasma membrane

Oncogene327777872013

10.1038/onc.2012.86

22410782

119

Matter

Ruoslahti

A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription

J Biol Chem27627757277632001

10.1074/jbc.M102014200

11333270

120

Egeblad

Werb

New functions for the matrix metalloproteinases in cancer progression

Nat Rev Cancer21611742002

10.1038/nrc745

11990853

121

Sand

Larsen

Hogaboam

Martinez

Han

Røssel Larsen

Nawrocki

Zheng

Karsdal

Leeming

MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis-validation of two novel biomarker assays

PLoS One8e849342013

10.1371/journal.pone.0084934

24376856

122

Bokhari

Baker

Dorjbal

Waheed

Zahn

Hamilton

Maxwell

Syed

Nestin suppression attenuates invasive potential of endometrial cancer cells by downregulating TGF-β signaling pathway

Oncotarget769733697482016

10.18632/oncotarget.11947

27626172

123

da Silva Cardeal

Brohem

Corrêa

Winnischofer

Nakano

Boccardo

Villa

Sogayar

Maria-Engler

Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence

Biochem Cell Biol847137192006

10.1139/o06-084

17167534

124

Cardeal

Boccardo

Termini

Rabachini

Andreoli

di Loreto

Longatto Filho

Villa

Maria-Engler

HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: Possible implications in cervical carcinogenesis

PLoS One7e335852012

10.1371/journal.pone.0033585

22438955

125

Shiau

Fan

Yang

Tsao

Lee

Cheng

Lai

Chang

Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas

PLoS One8e544232013

10.1371/annotation/a50fa759-93fb-444d-9523-9d4a805ef898

23349885

126

Ding

Pan

Liu

Jiang

Jiao

Elevation of MiR-9-3p suppresses the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells via down-regulating FN1, ITGB1 and ITGAV

Cancer Biol Ther184144242017

10.1080/15384047.2017.1323585

28613134

127

Wang

Deng

Huang

Cai

Zhu

Liu

Wang

Zhang

Zheng

High expression of Fibronectin 1 suppresses apoptosis through the NF-κB pathway and is associated with migration in nasopharyngeal carcinoma

Am J Transl Res9450245112017

29118912

128

Rajkumar

Sabitha

Vijayalakshmi

Shirley

Bose

Gopal

Selvaluxmy

Identification and validation of genes involved in cervical tumourigenesis

BMC Cancer11802011

10.1186/1471-2407-11-80

21338529

129

Koromilas

Sexl

The tumor suppressor function of STAT1 in breast cancer

JAKSTAT2e233532013

24058806

130

Zhang

Liu

STAT1 in cancer: Friend or foe?

Discov Med2419292017

28950072

131

Akram

Kim

Shin

Noh

Kim

Majid

Chang

Kim

Bae

Selective inhibition of JAK2/STAT1 signaling and iNOS expression mediates the anti-inflammatory effects of coniferyl aldehyde

Chem Biol Interact2561021102016

10.1016/j.cbi.2016.06.029

27378624

Figure 1.

Flow diagram of the present study. FC, fold change; DEGs, differentially expressed genes; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins; GO, Gene Ontology; FDR, false discovery rate; KEGG, Kyto Encyclopedia of Genes and Genomes; PPI, protein-protein interaction.

Figure 2.

Gene ontology enrichment analysis of hub genes for phase I, II, III and IV. The number in each phase represents the gene count.

Figure 3.

Comprehensive pathways crosstalk analysis. (A) Combination of pathways crosstalk analysis for the four phases and the (B) subnetwork with nodal degree ≥5. Green, phase I; yellow, phase II; orange, phase III; red, phase IV. The arrow represents the up/downstream associations between the pathways. MAPK signaling pathway (degree=33), PI3K-Akt signaling pathway (degree=21) and Focal adhesion (degree=15) rank as the top three pathways, whereby the majority of other pathways transfer information with them.

Figure 4.

Protein-protein interaction network analysis. (A) Protein-protein interaction network downloaded from The Protein Interaction Network Analysis platform and (B) subnetwork with nodal degree ≥5. Green, phase I; blue, phase II; yellow, phase II; red, phase IV. The nodal size represents the degree of each node. CDK1 (degree=16), FN1 (degree=12) and ITGB1 (degree=8) rank as the top three proteins. MMP9 was self-regulated and co-expressed with FN1 and ITGB1.

Figure 5.

Gene-pathway flowchart for the key genes and the pathways in phases I–IV. Circle, gene; rectangle, pathway. CDK1 and CCNB1 regulate the cell cycle and they are activated in phase I. For phases II–IV, ‘pathways in cancer’, ‘focal adhesion’ and ‘PI3K-Akt signaling pathway’ rank as the top three pathways according to the number of genes involved.

Figure 6.

Co-expression analyses for the key genes. Positive correlation was detected between CDK1 and CCNB1; between FN1 and ITGB1, and MMP9, and between STAT1 and MMP9. Color in each grid represents the correlation coefficient between two genes. The values in the color legend represent the correlation coefficient. *P<0.05, **P<0.01, ***P<0.001.

Figure 7.

Survival analysis for the key genes. (A) FN1, (B) ITGB1, (C) CDK1 and (D) CCNB1, (E) MMP9 and (F) STAT1. ITGB1 and FN1 have significant effect on overall survival.

Table I.

Hub genes in phases I–IV.

Phase	Gene	Regulation	Counts	LogFC	P-value
Phase I	CDK1	+	7	1.24	<0.01
	KIF11	+	7	1.27	0.01
	BUB1B	+	6	1.13	0.02
	BUB1	+	5	1.17	0.01
	CCNA2	+	5	1.01	<0.01
	HLA-DPA1	+	5	1.49	0.03
	CENPE	+	5	1.36	0.02
	RHOA	+	4	1.47	<0.01
	KIF15	+	4	1.11	<0.01
	CCNB1	+	4	1.23	0.01
	NDC80	+	4	1.47	0.01
	TTK	+	4	1.14	<0.01
	STAT1	–	4	−1.47	0.03
	CXCL10	+	4	2.47	<0.01
	KIF23	+	4	1.48	0.01
	KIF4A	+	3	1.00	0.05
	PSMB9	+	3	1.12	0.03
	GNG2	+	3	1.26	0.04
	SPAG5	+	2	1.15	0.01
	TRIP13	+	2	1.09	0.02
	ANLN	+	2	1.19	0.02
	CDKN3	+	2	1.83	<0.01
	KIF14	+	2	1.15	0.01
	MKI67	+	2	1.45	0.01
	NUSAP1	+	2	1.22	0.02
	NEK2	+	2	1.30	0.01
	NCAPG	+	2	1.18	<0.01
	DLGAP5	+	2	1.54	<0.01
	GBP1	+	2	1.45	<0.01
Phase II	STAT1	–	9	−1.03	0.02
	CXCL10	–	6	−2.16	0.02
	CXCL12	–	6	−1.48	0.04
	DCN	–	6	−1.37	0.01
	CCL2	–	5	−1.54	0.01
	KIT	–	5	−1.26	0.05
	IGF1	–	5	−1.86	<0.01
	OAS2	–	4	−1.37	0.01
	IRF7	–	4	−1.08	0.01
	ISG15	–	4	−1.83	0.02
	FN1	–	4	−1.34	0.04
	HGF	–	4	−1.22	0.02
	HERC6	–	3	−1.71	<0.01
	MX2	–	3	−1.86	0.01
	IFIT3	–	3	−1.79	<0.01
	IFIT1	–	3	−2.96	<0.01
	GBP1	–	3	−1.20	0.01
	CDC6	+	3	1.40	0.01
	IFIT5	–	2	−1.11	<0.01
	IFI6	–	2	−1.55	0.01
	SP110	–	2	−1.43	<0.01
	IFI44	–	2	−1.87	<0.01
	DDX60	–	2	−1.18	<0.01
	IFIT2	–	2	−1.67	<0.01
	RSAD2	–	2	−2.66	<0.01
Phase III	BIRC5	+	9	1.13	<0.01
	TOP2A	+	8	1.36	<0.01
	KIF2C	+	6	1.04	<0.01
	MCM10	+	6	1.16	0.01
	VEGFA	+	6	1.27	<0.01
	MAD2L1	+	5	1.03	<0.01
	KIF15	+	5	1.45	<0.01
	ASPM	+	5	1.70	<0.01
	FOXM1	+	5	1.18	0.01
	MX2	+	4	1.34	0.01
	STAT1	+	4	1.20	<0.01
	PLXNA4	–	4	−1.15	0.01
	AR	–	4	−1.69	<0.01
	CCND1	–	3	1.20	<0.01
	OAS2	+	3	1.05	<0.01
	ACLY	+	3	1.55	0.01
	GNG2	+	3	−1.21	<0.01
	RSAD2	+	2	1.85	<0.01
	ISG15	+	2	1.82	<0.01
	IFI35	+	2	1.35	0.01
	IRF5	+	2	1.46	<0.01
	SAMHD1	+	2	1.05	<0.01
	MKI67	+	2	1.20	<0.01
	PLK4	+	2	1.03	0.01
	AHCTF1	+	2	1.03	<0.01
	NUDC	+	2	1.07	<0.01
	EXO1	+	2	1.29	<0.01
	PLXNA3	+	2	1.01	0.01
	MMP9	+	2	2.55	<0.01
	PLAUR	+	2	1.01	<0.01
Phase IV	PIK3CA	+	9	1.42	<0.01
	CXCL8	+	8	1.28	0.05
	ITGB1	+	8	2.20	<0.01
	PTK2	+	8	1.33	<0.01
	GNG2	+	6	1.18	0.05
	ITGA1	+	6	1.33	<0.01
	GNG12	–	6	−1.14	<0.01
	FOS	–	5	−1.13	0.05
	EDN1	+	5	1.07	<0.01
	NMU	–	4	−2.23	<0.01
	LPAR5	–	4	−1.36	<0.01
	STAT1	+	3	1.75	<0.01
	FN1	+	3	3.61	<0.01
	GSTM1	–	3	−1.09	0.02
	PLA2G4A	–	3	−1.41	0.02
	CXCR4	+	2	1.58	<0.01
	HCAR3	–	2	−1.60	<0.01
	S1PR5	–	2	−1.56	<0.01
	CXCL5	–	2	−2.10	0.01
	NQO1	–	2	−1.38	0.01
	CXCL11	+	2	1.69	0.02
	COMP	+	2	1.62	0.01
	MAPK12	+	2	1.38	<0.01

+, upregulated; -, downregulated.

Table II.

Pathway enrichment analysis for phases I–IV.

Phase	Pathway	FDR	Involved genes
Phase I	Cell cycle	<0.001	CDK1, TTK, CCNA2, BUB1, CCNB1, BUB1B
	Progesterone-mediated oocyte maturation	0.002	CDK1, CCNA2, BUB1, CCNB1
	Chemokine signaling pathway	0.006	RHOA, CXCL10, STAT1, GNG2
	Oocyte meiosis	0.018	CDK1, BUB1, CCNB1
	NOD-like receptor signaling pathway	0.036	RHOA, GBP1, STAT1
	Influenza A	0.036	HLA-DPA1, CXCL10, STAT1
	Tuberculosis	0.037	RHOA, HLA-DPA1, STAT1
	Herpes simplex infection	0.038	CDK1, HLA-DPA1, STAT1
	Viral carcinogenesis	0.044	RHOA, CDK1, CCNA2
	Epstein-Barr virus infection	0.044	CDK1, HLA-DPA1, CCNA2
Phase II	Influenza A	<0.001	CCL2, OAS2, IRF7, RSAD2, CXCL10, STAT1
	NOD-like receptor signaling pathway	<0.001	GBP1, CCL2, OAS2, IRF7, STAT1
	Herpes simplex infection	<0.001	CCL2, OAS2, IRF7, IFIT1, STAT1
	Pathways in cancer	0.001	HGF, IGF1, FN1, KIT, CXCL12, STAT1
	Hepatitis C	0.001	OAS2, IRF7, IFIT1, STAT1
	Cytokine-cytokine receptor interaction	0.001	HGF, CCL2, KIT, CXCL10, CXCL12
	RIG-I-like receptor signaling pathway	0.003	IRF7, ISG15, CXCL10
	Chemokine signaling pathway	0.003	CCL2, CXCL10, CXCL12, STAT1
	Genes encoding secreted soluble factors	0.003	HGF, CCL2, IGF1, CXCL10, CXCL12
	Proteoglycans in cancer	0.004	HGF, IGF1, FN1, DCN
	AGE-RAGE signaling pathway in diabetic complications	0.005	CCL2, FN1, STAT1
	Toll-like receptor signaling pathway	0.006	IRF7, CXCL10, STAT1
	Ensemble of genes encoding extracellular matrix and extracellular matrix-associated proteins	0.008	HGF, CCL2, IGF1, FN1, DCN, CXCL10, CXCL12
	Measles	0.009	OAS2, IRF7, STAT1
	PI3K-Akt signaling pathway	0.015	HGF, IGF1, FN1, KIT
	Focal adhesion	0.024	HGF, IGF1, FN1
	Rap1 signaling pathway	0.026	HGF, IGF1, KIT
	Ras signaling pathway	0.029	HGF, IGF1, KIT
	Ensemble of genes encoding ECM-associated proteins including ECM-affilaited proteins, ECM regulators and secreted factors	0.032	HGF, CCL2, IGF1, CXCL10, CXCL12
Phase III	Pathways in cancer	0.002	BIRC5, CCND1, MMP9, AR, STAT1, GNG2, VEGFA
	Bladder cancer	0.006	CCND1, MMP9, VEGFA
	Hepatitis B	0.011	BIRC5, CCND1, MMP9, STAT1
	Pancreatic cancer	0.012	CCND1, STAT1, VEGFA
	Proteoglycans in cancer	0.025	PLAUR, CCND1, MMP9, VEGFA
	AGE-RAGE signaling pathway in diabetic complications	0.027	CCND1, STAT1, VEGFA
Phase IV	Chemokine signaling pathway	<0.001	GNG12, CXCL11, CXCL5, PIK3CA, CXCR4, PTK2, STAT1, CXCL8, GNG2
	Pathways in cancer	<0.001	FN1, LPAR5, GNG12, ITGB1, PIK3CA, CXCR4, FOS, PTK2, STAT1, CXCL8, GNG2
	Fluid shear stress and atherosclerosis	<0.001	GSTM1, NQO1, MAPK12, PIK3CA, FOS, EDN1, PTK2
	Signaling of Hepatocyte Growth Factor Receptor	<0.001	ITGA1, ITGB1, PIK3CA, FOS, PTK2
	PI3K-Akt signaling pathway	<0.001	ITGA1, FN1, COMP, LPAR5, GNG12, ITGB1, PIK3CA, PTK2, GNG2
	B Cell Survival Pathway	<0.001	ITGA1, ITGB1, PIK3CA, FOS
	AGE-RAGE signaling pathway in diabetic complications	<0.001	MAPK12, FN1, PIK3CA, EDN1, STAT1, CXCL8
	Toll-like receptor signaling pathway	<0.001	MAPK12, CXCL11, PIK3CA, FOS, STAT1, CXCL8
	Aspirin Blocks Signaling Pathway Involved in Platelet Activation	<0.001	PLA2G4A, ITGA1, ITGB1, PTK2
	Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia	<0.001	ITGA1, ITGB1, PIK3CA, PTK2
	Pertussis	<0.001	MAPK12, CXCL5, ITGB1, FOS, CXCL8
	Focal adhesion	<0.001	ITGA1, FN1, COMP, ITGB1, PIK3CA, PTK2
	TNF signaling pathway	<0.001	MAPK12, CXCL5, PIK3CA, FOS, EDN1
	Leukocyte transendothelial migration	<0.001	MAPK12, ITGB1, PIK3CA, CXCR4, PTK2
	Regulation of actin cytoskeleton	<0.001	ITGA1, FN1, GNG12, TGB1, PIK3CA, PTK2
	VEGF signaling pathway	<0.001	PLA2G4A, MAPK12, PIK3CA, PTK2
	PTEN dependent cell cycle arrest and apoptosis	<0.001	ITGB1, PIK3CA, PTK2
	uCalpain and friends in Cell spread	<0.001	ITGA1, ITGB1, PTK2
	Trefoil Factors Initiate Mucosal Healing	<0.001	ITGB1, PIK3CA, PTK2
	Prolactin signaling pathway	<0.001	MAPK12, PIK3CA, FOS, STAT1
	Leishmaniasis	<0.001	MAPK12, ITGB1, FOS, STAT1
	Inhibition of Cellular Proliferation by Gleevec	<0.001	PIK3CA, FOS, STAT1
	CXCR4 Signaling Pathway	<0.001	PIK3CA, CXCR4, PTK2
	TPO Signaling Pathway	<0.001	PIK3CA, FOS, STAT1
	Bacterial invasion of epithelial cells	<0.001	FN1, ITGB1, PIK3CA, PTK2
	mCalpain and friends in Cell motility	<0.001	ITGA1, ITGB1, PTK2
	ECM-receptor interaction	<0.001	ITGA1, FN1, COMP, ITGB1
	Small cell lung cancer	<0.001	FN1, ITGB1, PIK3CA, PTK2
	EGF Signaling Pathway	<0.001	PIK3CA, FOS, STAT1
	IL-17 signaling pathway	<0.001	MAPK12, CXCL5, FOS, CXCL8
	PDGF Signaling Pathway	<0.001	PIK3CA, FOS, STAT1
	Amoebiasis	<0.001	FN1, PIK3CA, PTK2, CXCL8
	Endocrine resistance	<0.001	MAPK12, PIK3CA, FOS, PTK2
	Proteoglycans in cancer	<0.001	MAPK12, FN1, ITGB1, PIK3CA, PTK2
	Chagas disease (American trypanosomiasis)	<0.001	MAPK12, PIK3CA, FOS, CXCL8
	Agrin in Postsynaptic Differentiation	<0.001	ITGA1, ITGB1, PTK2
	Integrin Signaling Pathway	<0.001	ITGA1, ITGB1, PTK2
	Fc Epsilon Receptor I Signaling in Mast Cells	<0.001	PLA2G4A, PIK3CA, FOS
	Cholinergic synapse	<0.001	GNG12, PIK3CA, FOS, GNG2
	Platelet activation	0.001	PLA2G4A, MAPK12, ITGB1, PIK3CA
	Osteoclast differentiation	0.001	MAPK12, PIK3CA, FOS, STAT1
	Dopaminergic synapse	0.001	MAPK12, GNG12, FOS, GNG2
	Hepatitis C	0.001	MAPK12, PIK3CA, STAT1, CXCL8
	Cytokine-cytokine receptor interaction	0.001	CXCL11, CXCL5, CXCR4, ACKR3, CXCL8
	Hepatitis B	0.001	PIK3CA, FOS, STAT1, CXCL8
	Phospholipase D signaling pathway	0.001	PLA2G4A, LPAR5, PIK3CA, CXCL8
	Shigellosis	0.001	MAPK12, ITGB1, CXCL8
	Fc epsilon RI signaling pathway	0.002	PLA2G4A, MAPK12, PIK3CA
	Influenza A	0.002	MAPK12, PIK3CA, STAT1, CXCL8
	Axon guidance	0.002	ITGB1, PIK3CA, CXCR4, PTK2
	Integrin Signaling Pathway	0.002	ITGA1, PIK3CA, PTK2
	Salmonella infection	0.003	MAPK12, FOS, CXCL8
	MAPKinase Signaling Pathway	0.003	MAPK12, FOS, STAT1
	Rap1 signaling pathway	0.003	MAPK12, LPAR5, ITGB1, PIK3CA
	Rheumatoid arthritis	0.003	CXCL5, FOS, CXCL8
	Th1 and Th2 cell differentiation	0.003	MAPK12, FOS, STAT1
	Circadian entrainment	0.003	GNG12, FOS, GNG2
	Inflammatory mediator regulation of TRP channels	0.003	PLA2G4A, MAPK12, PIK3CA
	Ras signaling pathway	0.003	PLA2G4A, GNG12, PIK3CA, GNG2
	Choline metabolism in cancer	0.003	PLA2G4A, PIK3CA, FOS
	Retrograde endocannabinoid signaling	0.003	MAPK12,GNG12,GNG2
	T cell receptor signaling pathway	0.004	MAPK12, PIK3CA, FOS
	Th17 cell differentiation	0.004	MAPK12, FOS, STAT1
	Serotonergic synapse	0.004	PLA2G4A, GNG12, GNG2
	Toxoplasmosis	0.004	MAPK12, ITGB1, STAT1
	Glutamatergic synapse	0.004	PLA2G4A, GNG12, GNG2
	MAPK signaling pathway	0.004	PLA2G4A, MAPK12, GNG12, FOS
	Sphingolipid signaling pathway	0.005	S1PR5, MAPK12, PIK3CA
	NOD-like receptor signaling pathway	0.012	MAPK12, STAT1, CXCL8
	cAMP signaling pathway	0.018	HCAR3, PIK3CA, FOS

FDR, false discovery rate.